06/09/22 9:44 AMNasdaq : BFRI, BFRIW low floatBiofrontera, Inc. Recognized for Rapid Sales Growth, Innovative Therapies and Marketing ExcellenceBiofrontera Inc. (Nasdaq: BFRI), aRHEA-AIpositive
05/31/22 10:42 AMNasdaq : BFRI, BFRIW conferenceslow floatBiofrontera Inc. to Participate in The Benchmark Healthcare House Call Virtual 1x1 ConferenceBiofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the Company will be participating in The Benchmark Healthcare House Call Virtual 1x1 Conference beingRHEA-AIneutral
05/24/22 11:29 AMNasdaq : BFRI, BFRIW low floatNew Data and Forecasts for the U.S. Skin Cancer Market Strongly Support the Commercial Opportunity for Biofrontera’s Ameluz®Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, views new data on skin cancer prevalence provided by the American Cancer Society 1, indicating approximately 3.4 millionRHEA-AIpositive
05/19/22 9:48 AMNasdaq : BFRI, BFRIW low floatBiofrontera Inc. Announces Closing of $9.4 Million Private PlacementBiofrontera Inc. (Nasdaq: BFRI) , a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the closing of its previously-announced $9.4 million private placement with a single institutionalRHEA-AIneutral
05/16/22 8:00 AMNasdaq : BFRI, BFRIW low floatBiofrontera Inc. Announces Pricing of $9.4 Million Private PlacementBiofrontera, Inc. (Nasdaq: BFRI; BFRIW), announced today that it has entered into a securities purchase agreement with a single institutional investor for the purchase of 3,419,000 shares of its common stock (or common stock equivalents in lieuRHEA-AIneutral
05/13/22 7:00 AMNasdaq : BFRI, BFRIW earningslow floatBiofrontera Inc. Reports First Quarter 2022 Financial Results and Provides a Business UpdateBiofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced financial results for the threeRHEA-AIneutral
05/06/22 8:25 AMNasdaq : BFRI, BFRIW conferencesearningslow floatBiofrontera Inc. to Report First Quarter Financial Results on May 13, 2022Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, will report financial results for the three months ended March 31, 2022 before the opening of the U.S. financial marketsRHEA-AIneutral
05/05/22 8:30 AMNasdaq : BFRI, BFRIW low floatBiofrontera Inc. to Showcase Actinic Keratosis Treatments at the Music City Symposium for Cosmetic Advances & Laser EducationBiofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today its sponsorship of the 17 th Edition of the MusicRHEA-AIpositive
04/21/22 1:20 PMNasdaq : BFRI, BFRIW low floatBiofrontera Launches New Patient-Focused Websites for Ameluz® and Xepi®Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization ofRHEA-AIneutral
04/13/22 10:10 AMNasdaq : BFRI, BFRIW fda approvallow floatBiofrontera Inc. Announces FDA Approval of Biofrontera Pharma GmbH as a Contract Laboratory for Ameluz®Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the U.S.RHEA-AIpositive
